Health Boards
Wed-30-03-2016, 13:54 PM
(Wed-30-03-2016, 11:00 AM)Fred Wrote:(Wed-30-03-2016, 01:22 AM)jiml Wrote: they obviously believe it will have similar effects on the disease as DMF ...
Yep
Quote:
XP23829 is protected by a U.S. composition-of-matter patent that currently has an expiration date of 2029. In addition XenoPort holds 48 issued patents worldwide, including those providing coverage for XP23829 and other MMF prodrug compositions and their uses, crystalline forms of XP23829, methods of treatment with MMF prodrugs and oral dosage forms.
XP23829 has novel chemical structure that produces the same active metabolite as TECFIDERA (dimethylfumarate)
So they are working around Tecfidera. That might be nice.
It also might be nice if they would be able to actually reduce the intestine problems lots of people have with the DMF, while still reaching the same results.
U.S. composition-of-matter patent...... Sound like a typical workaround patents possibility, we should have an E.U. composition-of-matter patent also, that would make things easier.
